Table 1. Prevalence of polypharmacy and baseline characteristics.
| Characteristics | Total population n=1 876 527 |
Cumulative polypharmacy (6-month window) n=1 405 654 |
Cumulative polypharmacy (1-month window) n=1 211 378 |
Consecutive polypharmacy (6-month window) n=470 873 |
|---|---|---|---|---|
| % (95% CI) | P% (95% CI) | P% (95% CI) | P% (95% CI) | |
| Overall | 100 | 74.907 (74.845 to 74.969) |
64.554 (64.486 to 64.623) |
7.615 (7.577 to 7.653) |
| Sex | ||||
| Female | 52.897 (52.825 to 52.968) |
77.825 (77.744 to 77.907) |
68.359 (68.267 to 68.45) |
9.060 (9.003 to 9.116) |
| Male | 47.103 (47.032 to 47.175) |
71.630 (71.536 to 71.724) |
60.282 (60.18 to 60.384) |
5.993 (5.943 to 6.042) |
| Age group | ||||
| 65–69 | 37.600 (37.531 to 37.669) |
74.713 (74.611 to 74.814) |
63.550 (63.438 to 63.662) |
6.923 (6.863 to 6.982) |
| 70–74 | 20.553 (20.495 to 20.611) |
76.583 (76.45 to 76.717) |
66.415 (66.266 to 66.564) |
8.546 (8.458 to 8.634) |
| 75–79 | 17.414 (17.36 to 17.468) |
77.010 (76.865 to 77.154) |
67.403 (67.243 to 67.564) |
8.921 (8.824 to 9.019) |
| 80–84 | 13.626 (13.576 to 13.675) |
75.129 (74.961 to 75.296) |
65.546 (65.362 to 65.73) |
8.048 (7.943 to 8.154) |
| ≥85 | 10.808 (10.763 to 10.852) |
68.729 (68.528 to 68.931) |
58.667 (58.453 to 58.882) |
5.602 (5.502 to 5.702) |
| Fund | ||||
| Civil Servants | 42.017 (41.946 to 42.087) |
82.952 (82.869 to 83.035) |
72.569 (72.47 to 72.667) |
9.439 (9.374 to 9.504) |
| Rural | 31.344 (31.277 to 31.41) |
59.055 (58.929 to 59.18) |
48.305 (48.178 to 48.433) |
1.865 (1.831 to 1.9) |
| Iranian and Universal Health Insurance | 16.747 (16.694 to 16.801) |
77.356 (77.21 to 77.503) |
65.598 (65.432 to 65.765) |
5.466 (5.387 to 5.546) |
| Other Social Strata | 9.739 (9.697 to 9.781) |
87.317 (87.165 to 87.47) |
80.789 (80.608 to 80.97) |
22.066 (21.875 to 22.256) |
| Foreign Citizens | 0.154 (0.148to 0.159) |
55.312 (53.497 to 57.128) |
44.757 (42.941 to 46.573) |
0 |
P, prevalence.